Sanofi-Aventis, Stanford in Research Pact

Sanofi-Aventis has entered a research collaboration through the Stanford University Bio-X program that supports, organizes and facilitates collaborative research projects in the early phases of development.

A Stanford Bio-X and Sanofi-Aventis joint steering committee will fund as many as five programs a year. Sanofi will fund an annual research forum that will bring together researchers from both parties to share knowledge and perspectives on scientific matters and research projects funded through the collaboration.

“Our approach to R&D must ensure we are at the center of the most innovative science, whether inside our own walls or through external partnerships, in order to continue to advance scientific knowledge and address patients’ unmet medical needs,” said Dr. Paul Chew, senior vice president, U.S. chief science officer and chief medical officer, Sanofi-Aventis U.S. ”Stanford is a world-class institution and Sanofi-Aventis is delighted to collaborate with its team of scientists who share a common vision of developing healthcare solutions through scientific discoveries and innovation across various disciplines. Bio-X researchers are exploring novel approaches needed in science today to accelerate the potential for scientific breakthroughs.”